Logo

Cytokinetics, Incorporated

CYTK

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin act… read more

Healthcare

Biotechnology

20 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$53.01

Price

+6.55%

$3.26

Market Cap

$6.343b

Mid

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-14838.8%

EBITDA Margin

-16244.7%

Net Profit Margin

-15299.8%

Free Cash Flow Margin
Revenue

$85.738m

-50.2%

1y CAGR

-36.0%

3y CAGR

-20.4%

5y CAGR
Earnings

-$606.311m

-0.8%

1y CAGR

-32.5%

3y CAGR

-36.3%

5y CAGR
EPS

-$5.11

+0.9%

1y CAGR

-21.0%

3y CAGR

-21.7%

5y CAGR
Book Value

-$368.720m

$1.226b

Assets

$1.594b

Liabilities

$858.058m

Debt
Debt to Assets

70.0%

-1.6x

Debt to EBITDA
Free Cash Flow

-$440.477m

-1.2%

1y CAGR

-32.5%

3y CAGR

-2268.1%

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases